Tokai Pharma (TKAI) Will Discontinue Enrollment in ARMOR2 Expansion Trial

August 22, 2016 4:03 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Tokai Pharma (NASDAQ: TKAI) disclosed the following on Monday:

Item 7.01. Regulation FD Disclosure

Tokai Pharmaceuticals, Inc. (“Tokai”) has determined to discontinue enrollment in its ongoing ARMOR2 expansion clinical trial of galeterone in metastatic castration-resistant prostate cancer (“mCRPC”) patients with acquired resistance to Xtandi® (enzalutamide) and not to proceed at this time with its planned study of galeterone in mCRPC patients who rapidly progress on either enzalutamide or Zytiga® (abiraterone acetate). Tokai is continuing to evaluate the unblinded data from its recently discontinued ARMOR3 clinical trial comparing galeterone to enzalutamide in treatment-naïve mCRPC patients whose prostate tumors express the AR-V7 splice variant, and is assessing potential next steps in its galeterone program.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News

Add Your Comment